Table 1.
Section/topic | Item No | Guidance for reporting | Reported in section |
---|---|---|---|
Title | |||
Title | 1 | Identify the study as an economic evaluation and specify the interventions being compared | — |
Abstract | |||
Abstract | 2 | Provide a structured summary that highlights context, key methods, results, and alternative analyses | — |
Introduction | |||
Background and objectives | 3 | Give the context for the study, the study question, and its practical relevance for decision making in policy or practice | — |
Methods | |||
Health economic analysis plan | 4 | Indicate whether a health economic analysis plan was developed and where available | — |
Study population | 5 | Describe characteristics of the study population (such as age range, demographics, socioeconomic, or clinical characteristics) |
— — — |
Setting and location | 6 | Provide relevant contextual information that may influence findings | — |
Comparators | 7 | Describe the interventions or strategies being compared and why chosen | — |
Perspective | 8 | State the perspective(s) adopted by the study and why chosen | — |
Time horizon | 9 | State the time horizon for the study and why appropriate | — |
Discount rate | 10 | Report the discount rate(s) and reason chosen | — |
Selection of outcomes | 11 | Describe what outcomes were used as the measure(s) of benefit(s) and harm(s) | — |
Measurement of outcomes | 12 | Describe how outcomes used to capture benefit(s) and harm(s) were measured | — |
Valuation of outcomes | 13 | Describe the population and methods used to measure and value outcomes | — |
Measurement and valuation of resources and costs | 14 | Describe how costs were valued | — |
Currency, price date, and conversion | 15 | Report the dates of the estimated resource quantities and unit costs, plus the currency and year of conversion | — |
Rationale and description of model | 16 | If modelling is used, describe in detail and why used. Report if the model is publicly available and where it can be accessed | — |
Analytics and assumptions | 17 | Describe any methods for analysing or statistically transforming data, any extrapolation methods, and approaches for validating any model used | — |
Characterizing heterogeneity | 18 | Describe any methods used for estimating how the results of the study vary for subgroups | — |
Characterizing distributional effects | 19 | Describe how impacts are distributed across different individuals or adjustments made to reflect priority populations | — |
Characterizing uncertainty | 20 | Describe methods to characterise any sources of uncertainty in the analysis | — |
Approach to engagement with patients and others affected by the study | 21 | Describe any approaches to engage patients or service recipients, the general public, communities, or stakeholders (such as clinicians or payers) in the design of the study | — |
Results | |||
Study parameters | 22 | Report all analytic inputs (such as values, ranges, references) including uncertainty or distributional assumptions | — |
Summary of main results | 23 | Report the mean values for the main categories of costs and outcomes of interest and summarise them in the most appropriate overall measure | — |
Effect of uncertainty | 24 | Describe how uncertainty about analytic judgments, inputs, or projections affect findings. Report the effect of choice of discount rate and time horizon, if applicable | — |
Effect of engagement with patients and others affected by the study | 25 | Report on any difference patient/service recipient, general public, community, or stakeholder involvement made to the approach or findings of the study | — |
Discussion | |||
Study findings, limitations, generalizability, and current knowledge | 26 | Report key findings, limitations, ethical or equity considerations not captured, and how these could affect patients, policy, or practice | — |
Other relevant information | |||
Source of funding | 27 | Describe how the study was funded and any role of the funder in the identification, design, conduct, and reporting of the analysis | — |
Conflicts of interest | 28 | Report authors conflicts of interest according to journal or International Committee of Medical Journal Editors requirements | — |